Immune checkpoint blockade targeting PD-1/PD-L1 and CTLA-4 has markedly changed the paradigm of cancer therapy, providing durable clinical benefit to patients with various types of cancer [1–3]. This evidence concerns the gene CTLA4 and cancer.